CD Biosynsis offers high-efficiency Sf9 Cells Multi-Gene Knockout Strain Construction Services, providing permanent and precise deletion or disruption of multiple target genes in this foundational insect cell line. Sf9 cells (derived from Spodoptera frugiperda) are widely used in the Baculovirus Expression Vector System (BEVS) for producing complex recombinant proteins. Multi-gene knockout is a critical step in advanced host cell engineering, utilized primarily to systematically eliminate multiple competing pathways, remove redundant product-degrading proteases, or fully disrupt complex native glycosylation pathways (e.g., removing all fucosylation and galactosylation enzymes). Leveraging the precision of multiplex CRISPR-Cas9 to induce simultaneous double-strand breaks (DSBs), our services rely on the cell's Non-Homologous End Joining (NHEJ) pathway to generate stable, loss-of-function mutations. We accelerate the development of superior Sf9 cell lines with enhanced product stability and tailored humanized glycosylation profiles.
Get a QuoteAchieving multiple gene knockouts in Sf9 cells is crucial for engineering complex traits like full humanized glycosylation. Our platform is optimized to address this by focusing on high-efficiency, transient delivery of the editing machinery (RNP) and the use of multiplex gRNA arrays. This ensures that multiple DSBs are created simultaneously at different loci. The repair via the error-prone NHEJ pathway generates frameshift mutations (indels) that functionally disrupt the genes in a single step. This strategy is essential for creating highly customized Sf9 chassis strains, such as protease-deficient lines or hosts capable of producing therapeutic proteins with minimal immunogenic glycan structures.
gRNA Array Design
Rational design of multiple guide RNAs (gRNAs) simultaneously targeting the early coding region of 2 to 5 genes to maximize the chance of multi-locus, frame-shift mutations via NHEJ.
Single vs. Sequential Knockout
Strategy optimization based on gene function; performing simultaneous knockouts for non-essential targets (e.g., proteases) or sequential editing for complex, multi-step pathway deletions (e.g., glycosylation).
Indel Verification Primers
Design of robust primers for rapid screening and clone-level verification of successful indel formation at all targeted loci using TIDE or Sanger sequencing.
RNP Delivery System
Preference for Ribonucleoprotein (RNP) delivery for transient, high-efficiency, and low off-target activity, maximizing editing speed and genetic integrity in the insect host.
Pol III Multiplex Cassettes
Construction of Pol III promoter-driven gRNA expression cassettes (e.g., U6/H1) to ensure robust, simultaneous expression of all gRNAs necessary for multi-locus cleavage.
Selection Marker Strategy
Use of co-transfected selection markers or integrated markers (and recycling strategies) to enrich for the cell population that has undergone the desired multi-gene editing event.
Humanized Glycoengineering
Systematic deletion of multiple native glycosylation genes (e.g., FUT, GNT, beta-galactosidases) to eliminate immunogenic insect glycans and prepare the chassis for mammalian enzyme knock-in.
Protease System Disruption
Deletion of multiple host cell proteases (e.g., cathepsins, metalloproteases) to eliminate product degradation and ensure high integrity of the secreted recombinant protein.
Enhanced Folding Capacity
Targeted knockout of regulatory genes that limit the expression of ER-resident chaperones and folding enzymes, indirectly enhancing the host's capacity for complex protein production.
A systematic process for achieving multiplex disruption and stable clone isolation.
1. Multiplex Design & RNP Preparation
2. Transfection & Multi-Locus Editing
3. Single Cell Cloning & Screening
4. Clone Verification & Delivery
Identify all target genes (2+ loci). Design and synthesize the multiplex gRNA array targeting all loci simultaneously.
Prepare the Cas9 enzyme/multiplex gRNA Ribonucleoprotein (RNP) complex for transient delivery.
Design multi-locus verification strategy (e.g., multiplex PCR, TIDE sequencing).
Deliver the RNP complex (and selection marker if required) into the Sf9 host cell line via optimized electroporation.
Culture cells to allow the NHEJ repair pathway to finalize the genomic edit at all targeted loci.
Apply antibiotic selection or FACS sorting to enrich for edited clones with high editing frequency.
Genotype verification via TIDE/Sanger sequencing of all target loci to confirm indel formation in every targeted gene.
Phenotypic validation of the final clone for multi-gene function and long-term stability.
Delivery of the verified Sf9 master cell bank (MCB) and comprehensive documentation.
Multiplex RNP Efficiency
Use of multiplex RNP delivery achieves simultaneous disruption of multiple genes in a single transfection step, dramatically accelerating the complex chassis engineering timeline.
Glycan Pathway Elimination
Enables the complete knockout of native immunogenic glycosylation enzymes (e.g., FUT, GNT), creating a neutral chassis for subsequent humanization efforts.
Enhanced Product Integrity
Systematic removal of multiple protease genes ensures the final secreted or intracellular product is protected from host cell degradation, maximizing purity and yield.
Rapid Clonal Isolation
Integration of HTS and automated single-cell cloning rapidly isolates rare, multi-edited clones, shortening the development timeline required to establish the Master Cell Bank (MCB).
1. How do you ensure knockout of all targeted genes simultaneously?
We use a high concentration of the multiplex RNP complex to generate simultaneous DSBs at all targeted sites. Clones are then extensively screened via sequencing (TIDE) to confirm disruptive indels in every targeted gene.
2. Why is multi-gene knockout necessary for humanized glycoengineering?
To produce human-compatible proteins, multiple native insect glycosylation enzymes that add immunogenic sugars must be eliminated. This requires the simultaneous or sequential knockout of several host genes (e.g., those responsible for alpha(1,3)-fucose and beta(1,4)-galactose addition).
3. What is the role of NHEJ in multi-gene knockout?
NHEJ (Non-Homologous End Joining) is the error-prone repair pathway utilized. It generates frame-shift mutations (indels) when repairing the simultaneous Cas9 cuts, thus functionally disrupting multiple genes at once.
4. What types of protease genes are commonly targeted for multi-knockout?
We typically target secreted and intracellular host cell proteases (HCPs) known to degrade complex recombinant proteins, such as cathepsins, ensuring maximal product integrity during the BEVS lytic cycle.
5. How is the final multi-gene knockout clone verified?
Verification includes multiplex PCR to confirm overall locus disruption, TIDE/Sanger sequencing of every targeted locus, and functional assays (e.g., loss of native glycan activity) to confirm the desired phenotype.
6. Can you combine multi-gene knockout with gene knock-in in one project?
Yes. A common strategy involves using multi-gene knockout to create a protease/glycan-deficient chassis, followed by a CRISPR/HDR gene knock-in to stably integrate the therapeutic gene and the required human glycosylation pathway genes.
7. What input is required to start a multi-gene knockout project?
We require the specific Sf9 host cell line (Sf9/Hi5) and a prioritized list of 2 or more genes (locus tags or sequences) targeted for complete functional disruption, along with the desired final product.
8. What is the biggest advantage of a multi-knockout Sf9 chassis?
The biggest advantage is the creation of a defined, universal chassis strain that offers vastly improved product quality (elimination of immunogenic glycans) and stability (no protease degradation), significantly enhancing the value of the final bioproduct.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.